AR093447A1 - Enriquecimiento de plasmablastos especificos de antigeno - Google Patents
Enriquecimiento de plasmablastos especificos de antigenoInfo
- Publication number
- AR093447A1 AR093447A1 ARP130104147A ARP130104147A AR093447A1 AR 093447 A1 AR093447 A1 AR 093447A1 AR P130104147 A ARP130104147 A AR P130104147A AR P130104147 A ARP130104147 A AR P130104147A AR 093447 A1 AR093447 A1 AR 093447A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- pbmc
- plasmablasts
- spleen
- specificity
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 19
- 102000036639 antigens Human genes 0.000 title abstract 19
- 108091007433 antigens Proteins 0.000 title abstract 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 20
- 210000003720 plasmablast Anatomy 0.000 abstract 16
- 206010061598 Immunodeficiency Diseases 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 8
- 210000000952 spleen Anatomy 0.000 abstract 8
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/46482—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Abstract
Reivindicación 1: Un método para obtener una población de plasmablastos enriquecida en plasmablastos que tienen especificidad para un antígeno, el método comprende obtener células mononucleares de sangre periférica (PBMC) de un donante, poner en contacto las PBMC con el antígeno o un fragmento o porción de este, para obtener una premezcla de PBMC/antígeno, transferir las PBMC al bazo de un animal inmunocomprometido y aislar los plasmablastos del bazo del animal inmunocomprometido, con lo cual se obtiene una población de plasmablastos enriquecida en plasmablastos que tienen especificidad para un antígeno. Reivindicación 7: Un método para el enriquecimiento de plasmablastos específicos de antígeno, el método comprende obtener células mononucleares de sangre periférica (PBMC) de un donante, poner en contacto las PBMC con por lo menos un antígeno, para obtener una premezcla de PBMC/antígeno, transferir las PBMC al bazo de un animal inmunocomprometido, y aislar los plasmablastos del bazo del animal inmunocomprometido, con lo cual se enriquecen plasmablastos específicos de antígeno. Reivindicación 14: Un método para identificar un plasmablasto capaz de producir un anticuerpo que tiene especificidad para un antígeno, el método comprende obtener células mononucleares de sangre periférica (PBMC) de un donante, poner en contacto las PBMC con por lo menos un antígeno para obtener una premezcla de PBMC/antígeno, transferir las PBMC al bazo de un animal inmunocomprometido aislar los plasmablastos del bazo del animal inmunocomprometido, y seleccionar células específicas de antígeno de los plasmablastos aislados, con lo cual se identifica un plasmablasto capaz de producir un anticuerpo que tiene especificidad para un antígeno. Reivindicación 17: Un método para identificar un plasmablasto capaz de producir un anticuerpo que tiene especificidad para más de un antígeno, el método comprende obtener células mononucleares de sangre periférica (PBMC) de un donante, poner en contacto las PBMC con dos o más antígenos diferentes para obtener una premezcla de PBMC/antígeno, transferir las PBMC al bazo de un animal inmunocomprometido aislar los plasmablastos del bazo del animal inmunocomprometido y seleccionar células específicas de antígeno de los plasmablastos aislados, con lo cual se identifica un plasmablasto capaz de producir un anticuerpo que tiene especificidad para un antígeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725764P | 2012-11-13 | 2012-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093447A1 true AR093447A1 (es) | 2015-06-10 |
Family
ID=49640215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104147A AR093447A1 (es) | 2012-11-13 | 2013-11-12 | Enriquecimiento de plasmablastos especificos de antigeno |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140134638A1 (es) |
| EP (1) | EP2920300B1 (es) |
| JP (1) | JP2015536145A (es) |
| KR (1) | KR20150084831A (es) |
| CN (1) | CN104822828A (es) |
| AR (1) | AR093447A1 (es) |
| AU (1) | AU2013344992A1 (es) |
| BR (1) | BR112015009933A2 (es) |
| CA (1) | CA2889266A1 (es) |
| HK (1) | HK1213009A1 (es) |
| IL (1) | IL238302A0 (es) |
| MX (1) | MX2015005862A (es) |
| RU (1) | RU2015116927A (es) |
| SG (1) | SG11201503706TA (es) |
| WO (1) | WO2014078280A1 (es) |
| ZA (1) | ZA201502711B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3408288A2 (en) | 2016-01-29 | 2018-12-05 | Achaogen, Inc. | Screening methods for identifying antibodies that bind cell surface epitopes |
| US11559044B2 (en) * | 2018-04-26 | 2023-01-24 | Hoffmann-La Roche Inc. | Method of and system for tracking an animal in a population of animals |
| WO2023150760A2 (en) * | 2022-02-04 | 2023-08-10 | Cornell University | Enrichment and characterization of rare circulating cells, including progenitor cells, from peripheral blood, and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993005796A1 (en) * | 1991-09-19 | 1993-04-01 | The Scripps Research Institute | Method for producing human antibodies in a non-human animal, and animals therefor |
| US5663481A (en) * | 1993-08-06 | 1997-09-02 | Mount Sinai Hospital Corporation | Animal model of the human immune system |
| US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| IL118625A0 (en) * | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibodies |
| EP1079688A1 (en) * | 1998-05-26 | 2001-03-07 | Innogenetics N.V. | Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies |
| AU2005323025A1 (en) * | 2004-12-31 | 2006-07-13 | Biogen Idec Ma Inc. | Polypeptides that bind BR3 and uses thereof |
| NZ572807A (en) * | 2006-05-19 | 2011-10-28 | Alder Biopharmaceuticals Inc | Culture method for obtaining a clonal population of antigen-specific b cells |
| JP5726744B2 (ja) * | 2008-11-21 | 2015-06-03 | カリフォルニア インスティチュート オブ テクノロジー | 生体外におけるヒトｂリンパ球産生培養システム |
| JP5781508B2 (ja) * | 2009-07-15 | 2015-09-24 | アイム・セラピューティクス・べー・フェー | 高親和性抗体を産生させるための手段および方法 |
| EP2703485B1 (en) * | 2011-03-30 | 2018-12-26 | National University Corporation University Of Toyama | Method for selecting plasma cells and plasmablasts, and method for producing target antigen-specific antibody |
| GB201212550D0 (en) * | 2012-07-13 | 2012-08-29 | Novartis Ag | B cell assay |
-
2013
- 2013-11-12 AR ARP130104147A patent/AR093447A1/es unknown
- 2013-11-12 RU RU2015116927A patent/RU2015116927A/ru not_active Application Discontinuation
- 2013-11-12 CN CN201380058934.4A patent/CN104822828A/zh active Pending
- 2013-11-12 JP JP2015542000A patent/JP2015536145A/ja active Pending
- 2013-11-12 KR KR1020157012137A patent/KR20150084831A/ko not_active Application Discontinuation
- 2013-11-12 WO PCT/US2013/069588 patent/WO2014078280A1/en active Application Filing
- 2013-11-12 AU AU2013344992A patent/AU2013344992A1/en not_active Abandoned
- 2013-11-12 MX MX2015005862A patent/MX2015005862A/es unknown
- 2013-11-12 BR BR112015009933A patent/BR112015009933A2/pt not_active IP Right Cessation
- 2013-11-12 EP EP13795394.9A patent/EP2920300B1/en not_active Not-in-force
- 2013-11-12 CA CA2889266A patent/CA2889266A1/en not_active Abandoned
- 2013-11-12 SG SG11201503706TA patent/SG11201503706TA/en unknown
- 2013-11-12 US US14/077,407 patent/US20140134638A1/en not_active Abandoned
-
2015
- 2015-04-15 IL IL238302A patent/IL238302A0/en unknown
- 2015-04-21 ZA ZA2015/02711A patent/ZA201502711B/en unknown
-
2016
- 2016-01-26 HK HK16100861.8A patent/HK1213009A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201502711B (en) | 2016-11-30 |
| CN104822828A (zh) | 2015-08-05 |
| RU2015116927A (ru) | 2017-01-10 |
| SG11201503706TA (en) | 2015-06-29 |
| CA2889266A1 (en) | 2014-05-22 |
| KR20150084831A (ko) | 2015-07-22 |
| JP2015536145A (ja) | 2015-12-21 |
| EP2920300A1 (en) | 2015-09-23 |
| WO2014078280A1 (en) | 2014-05-22 |
| BR112015009933A2 (pt) | 2017-12-12 |
| US20140134638A1 (en) | 2014-05-15 |
| IL238302A0 (en) | 2015-06-30 |
| EP2920300B1 (en) | 2018-09-12 |
| MX2015005862A (es) | 2015-09-10 |
| AU2013344992A1 (en) | 2015-05-14 |
| HK1213009A1 (zh) | 2016-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124717T1 (el) | Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων | |
| CY1122386T1 (el) | Χιμαιρικος υποδοχεας αντιγονων και μεθοδοι χρησης εξ αυτου | |
| CL2020001575A1 (es) | Anticuerpos anti-trem2 y métodos relacionados. | |
| CO2017000300A2 (es) | Moléculas con especificidad para cd45 y cd79 | |
| EA201890996A1 (ru) | Способ получения t-клеток для т-клеточной терапии | |
| CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
| CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| NI201500103A (es) | Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos. | |
| CR20150405A (es) | Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatorios | |
| AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
| AR091228A1 (es) | Metodo para producir un organismo mejorado vegetal infectado establemente con un endofito | |
| DOP2016000238A (es) | Sistema y método de mercadeo dirigido de selección previa digital | |
| BR112018069297A2 (pt) | composição, e, métodos para induzir uma resposta imune e para tratar um indivíduo que foi diagnosticado com uma doença ou distúrbio | |
| CR20140406A (es) | Anticuerpos cd47 y métodos de uso de los mismos | |
| CR20140441A (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| MX342073B (es) | Modelo de gramatica para consultas de busqueda estructuradas. | |
| EA201690731A1 (ru) | Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах | |
| BR112014013876A2 (pt) | vacina à base de toxina de clostridium difficile | |
| CO2019002608A2 (es) | Biomarcadores de arn para angioedema hereditario | |
| AR093447A1 (es) | Enriquecimiento de plasmablastos especificos de antigeno | |
| BR112014026440A2 (pt) | assays, methods and apparatus for assessing rna disruption | |
| AR105379A1 (es) | Dispositivo para detectar proteínas mal plegadas y sus métodos de uso | |
| JP2015536145A5 (es) | ||
| AR086030A1 (es) | Metodos y dispositivos para amplificar acidos nucleicos | |
| AR097591A1 (es) | Métodos para determinar la respuesta a la terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |